

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Perricaudet et al. Group Art Unit:  
Serial No: To Be Assigned Examiner:  
U.S. National Stage of PCT/FR94/00851  
Filed: Concurrently Herewith  
For: Defective Adenovirus Vectors and Use Thereof in Gene Therapy

To: The Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

CERTIFICATE OF MAILING (37 CFR 1.10)

GB761722720 US  
"Express Mail" Mailing Number

10 March 1995  
Date of Deposit

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner of Patents and Trademarks, Box PCT, Washington, DC 20231, Attn. DO/US.

Julie K. Smith  
(Type or print name of person mailing paper)

*Jul K St*  
(Signature of person mailing paper)

**SUBMISSION OF COMPUTER READABLE SEQUENCE  
LISTING PURSUANT TO 37 C.F.R. §§ 1.821 through 1.825**

Dear Sir:

In accordance with 37 C.F.R. §§ 1.821-1.825 relating to an Application Disclosure Containing Nucleotide and/or Amino Acid Sequences, I hereby certify, in accordance with §1.821(f), that the contents of the paper copy of the Sequence Listing and of the computer readable (CRF) Sequence Listing enclosed herewith are the same.

Rhône-Poulenc Rorer Inc.  
500 Arcola Road, 3C43  
Collegeville, PA 19426-0107  
Telephone: (610) 454-3839  
Facsimile: (610) 454-3808

Respectfully submitted,

*Jul K St*

Dated: 10 March 1995

Julie K. Smith, Ph.D.  
Agent for Applicants  
Registration No. 38,619